3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
2
Sponsor Class
OTHER
14
NIH
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Neuroblastoma
6
Glioblastoma
6
Melanoma
5
Neoplasms
3
Leukemia, Myeloid, Acute
3
Glioma
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Pathologic Complete Response
2
Ovarian Neoplasms
2
Osteosarcoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Gliosarcoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Wilms Tumor
1
Vaccinia
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Interventions
Prednisone
103
enzalutamide
76
Docetaxel
72
Abiraterone Acetate
68
Leuprolide
47
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
45
abiraterone
39
apalutamide
29
Prednisolone
27
bicalutamide
26
Zoledronic Acid
24
radium Ra 223 dichloride
22
pembrolizumab
22
darolutamide
22
Goserelin
22
Triptorelin Pamoate
17
cabazitaxel
16
Androgen Antagonists
15
sipuleucel-T
13
luprolide acetate gel depot
12
Injections
12
Dexamethasone
12
olaparib
11
gallium 68 PSMA-11
10
Mitoxantrone
10
Pluvicto
9
Ipilimumab
9
Dutasteride
9
Cyclophosphamide
9
relugolix
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostatic Neoplasms
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT01784913
2024-12-16
UV1/hTERT2012P
Ultimovacs ASA
Phase 1/2
Completed
22 enrolled
NCT01322490
2019-09-04
Prospect
Bavarian Nordic
Phase 3
Completed
1,297 enrolled
16 charts